Related Experiment Video
Updated: Oct 14, 2025
10:03
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.8K
Alpha-Synuclein Aggregation in Parkinson's Disease
E Srinivasan1,2, G Chandrasekhar1, P Chandrasekar1
1Bioinformatics Lab, Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology (Deemed to be University), Vellore, India.
Frontiers in Medicine
|November 4, 2021
Summary
Parkinson's disease involves the loss of brain cells and the misfolding of alpha-synuclein protein into amyloid structures. Understanding these molecular changes is key to developing future Parkinson's disease treatments.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder marked by the loss of dopaminergic neurons.
- While genetic factors are implicated, sporadic PD cases lack clear genetic links.
- Mitochondrial dysfunction and protein misfolding are key pathogenic pathways.
Purpose of the Study:
- To review the molecular understanding of alpha-synuclein in Parkinson's disease pathogenesis.
- To highlight the role of alpha-synuclein misfolding in neurodegeneration.
- To discuss the implications of genetic and elusive factors in PD.
Main Methods:
- Literature review of clinical and molecular findings in PD.
- Analysis of pathways involved in PD pathogenesis.
- Focus on alpha-synuclein's role, transcription by SNCA gene, and its aggregation.
Main Results:
- Alpha-synuclein misfolding into amyloid fibrillar structures is a major factor in PD prognosis.
- Aberrant alpha-synuclein contributes to neurodegeneration.
- The SNCA gene transcribes alpha-synuclein, crucial for synaptic function.
Conclusions:
- Alpha-synuclein's pathogenic transformation is central to Parkinson's disease.
- Further research is needed to elucidate genetic and other vulnerability factors in PD.
- Understanding alpha-synuclein's molecular mechanisms is vital for PD research.
Related Concept Videos
01:37Neural Regulation
40.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.5K
01:15Parkinson's Disease: Overview
828
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
828
01:24Parkinson's Disease: Treatment
441
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
441
03:03Amyloid Fibrils
10.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.7K